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cytokine-activated lymphocytes and
indicated that monocytes can form po-
dosomes and migrate through endo-
thelial cells; serial EM analyses have
suggested a prominent role for trans-
cellular migration of neutrophils (Feng
et al., 1998). These studies suggest
that most leukocytes are endowed
with podosome-sensing capabilities.
However, naive lymphocytes were in-
ept in transcellular migration, suggest-
ing that certain cytokines can activate
the podosome-formation machinery.
The remarkable ability of activated
lymphocytes to form invasive podo-
somes resembling invadopodia raises
other questions about what really
makes a tumor invasive. Conversely,
the essential function of podosomes
and their specificity for transcellular
migration raises the possibility that in-
vadopodia-enabled malignant tumors
might preferentially use the transcellu-
lar route to metastasize. Further elu-
cidation of this pathway will provide
targets that may impact the specificity
of the immune response and, poten-
tially, the behavior cancer cells.
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Immunoglobulin A (IgA) confers mucosal protection against bacteria in the intestine. In this issue, He
et al. (2007) find that bacterial molecules promote IgA2 generation via the cytokine APRIL, produced
by intestinal epithelial and dendritic cells.What a difference 30 mm makes. On
one side of the intestinal epithelium,
there are more microbes than we have
cells in our body. On the other, the tis-
sues of the gut mucosa are almost
sterile. The numbers of commensal
microbes in a human (1014) may be
startling enough, but their densities
(%1012/g intestinal contents) are much
higher than those in other global habi-
tats for microbial consortia, such as
soils, subsurfaces, andoceans (<108/g).
Not only are we the best of good cul-
ture media, but in any discussion of
host-microbial mutualism we are also
left wondering whether we tolerate
the commensalmicrobes or vice versa.
Immunology is bound to take a eu-
karyotic view of mutualism. We knowfrom studies of the recolonization of
germ-free experimental animals that
there are many mucosal and systemic
adaptations to the presence of a com-
mensal microbiota; among these, im-
munoglobulin A (IgA) induction was
one of the earliest characterized and
most dramatic. Despite this, evidence
for the function of IgA in mutualism
is indirect (Macpherson et al., 2005).
This conclusion is based on the limited
the penetration of test doses of in-
testinal bacteria, the occurrence of
low-grade intestinal damage when
the polymeric-immunoglobulin-recep-
tor (pIgR) transepithelial-transport sys-
tem (required for IgA secretion) is de-
ficient, and lymphoid hyperplasia in
activation-induced cytosine deami-Immunitnase (AID)-deficient animals, which are
incapable of Ig class-switch recombi-
nation. Despite these data, IgA is just
one of multiple layers of mucosal pro-
tection: The epithelial permeability
barrier is critical, IgM is also a substrate
for pIgR in mice and humans, and T
cell and innate mechanisms also play
a role. Presumably, the coevolution of
the intestinal microbiota andmammals
over the last 200 million years has
ensured redundancy in the system,
so isolated IgA deficiency in humans
or mice only has a weak phenotype.
Despite the redundancy, IgA has an
important role in protecting the expo-
sure of tissues underlying the epithe-
lium from the enormous concentration
of microbes and their potentiallyy 26, June 2007 ª2007 Elsevier Inc. 755
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Previewsdamaging molecules. IgA+ B cells are
certainly induced in the Peyer’s
patches, and previously the epithelium
has been thought to form the perme-
ability barrier and to transport IgA
into the intestinal lumen. In this issue
of Immunity, He et al. (2007) show that
class-switch recombination (CSR) to
IgA in B cells in the lamina propria of
the human colon is actually driven by
signals from colonic epithelial cells.
Different species have different
numbers of functional alpha chains in
the Ig heavy-chain locus, ranging from
eight in lagomorphs, such as rabbits,
to one in mice. Humans have two. IgA1
has a longer hinge region between the
Ca2 and Ca3 domains, and this might
improve the binding of IgA1 to adjacent
repetitive epitopes but makes it sus-
ceptible to IgA1 proteases produced
by bacteria, including pathogens. IgA1
dominates serum and most secre-
tions. IgA2 is not susceptible to most
bacterial IgA proteases, and it is the
dominant isotype secreted in the co-
lon, where the commensal microbial
load is highest.
Experiments in mice have shown
that functionally, IgA has rather Janus-
like qualities. On one hand, secretory
immunity is able to produce T help-
dependent high-affinity IgA that neu-
tralizes exotoxins, viruses, and patho-
genic bacteria. On the other hand,
there is a T independent system in
which undiversified IgA is secreted.
This IgA limits the penetration of com-
mensal microbes through the sur-
face epithelial layer and presumably
works as a low-affinity high-capacity
response to redundant surface epi-
topes (Macpherson et al., 2005).
In general, a class-switch recombi-
nation (CSR) requires two signals.
The first is through the cytokine TGF-b
with contributions from interleukin-2
(IL-2), IL-4, IL-5, IL-6, and IL-10, which
target transcription of the Ia promoters
that are upstream of the Ca exons and
the switch region preceding them. This
exposes the a switch region, which
can potentially be recombined at the
m switch region to place the variable-
diversity-joining (VDJ) segment next
to Ca after the removal of the interven-
ing DNA by the CSR machinery. For
similar CSR to happen with other iso-
types, a second signal is delivered by756 Immunity 26, June 2007 ª2007 ElseFigure 1. Proposed Model Linking Human Intestinal Epithelial Cells and Local
Lamina-Propria B Cell Class-Switch Recombination to IgA2
Intestinal epithelial cells (IEC) sense the presence of luminal bacteria via Toll-like receptors (TLR)
expressed on the luminal surface. TLR signaling leads to the production and secretion of APRIL
and BAFF by IEC. APRIL then directly induces local IgA1
+ B cells to sequentially switch to IgA2
via interaction with TACI, whereas BAFF likely acts to enhance B cell survival and proliferation.
IEC can also induce B cell CSR indirectly through secretion of TSLP, which is then sensed by lam-
ina-propria dendritic cells and stimulates the secretion of APRIL. Although themajority of the IgA2
+
B cells probably arise through sequential CSR from IgA1, APRIL can also induce CSR of IgD
+ and
IgG+ B cells.vligation of CD40 on B cells with its
ligand CD40L on T cells. However,
mouse-IgA induction can be T inde-
pendent (Macpherson et al., 2000)
and in mice deficient of CD40L or
CD40, IgA production is not abrogated
(Bergqvist et al., 2006). In view of these
discrepancies, other costimulatory
signals for a CSR in B cells have been
sought.
The tumor necrosis factor (TNF)
family includes two members—a B
cell-activation factor of the TNF family
(BAFF) and a proliferation-inducing
ligand (APRIL)—both of which have
been shown to stimulate CSR to IgG
and IgA in human (Litinskiy et al., 2002)
and mouse B cells (Castigli et al.,
2005). BAFF expression has mainly
been shown in monocytes and den-
dritic cells (DCs), whereas APRIL is ex-
pressed bymonocytes, macrophages,
DCs, and activated T cells. They have
three potential receptors on B cells—
BAFF-R, BCMA, and TACI; BAFF
binds all three receptors, but APRIL
binds only BCMA and TACI (Figure 1).
These signaling interactions have beenier Inc.investigated through the use of strains
with selective deficiencies. BAFF and
BAFF-R mice are deficient in B cells,
so they are not useful in determining
the requirements of IgA induction.
TACI-deficient mice have low IgA and
deficient immunization responses to
repetitive (type II) T independent anti-
gens (von Bulow et al., 2001). APRIL-
deficient mice are selectively deficient
in IgA (Castigli et al., 2004). In sorted
murine B cells, APRIL stimulates CSR
to IgG, IgA, and IgE via TACI, whereas
TACI-deficient B cells switch to IgG
and IgE, but not IgA, when stimulated
by BAFF (Castigli et al., 2005). These
results suggest that APRIL-TACI in-
teractions are necessary for IgA pro-
duction in vivo and potentially avoid
CD40-CD40L requirements for aCSR.
Although signals from APRIL but not
CD40 are essential for IgA CSR, the
relative importance of different sites
of CSR has been controversial. The
classical work of Cebra and Gowans
showed that IgA is induced in the ger-
minal centers of the Peyer’s patches,
and IgA plasmablasts recirculate
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ter the bloodstream and home back to
the mucosa, where they form IgA-se-
creting plasma cells. There is also evi-
dence for aCSR in marginal-zone B
cells and in murine pleuroperitoneal
B1 cells, although their contribution
to the intestinal secretory IgA is uncer-
tain (Macpherson et al., 2005). Further,
there is evidence in mice that naive
B cells switch locally in the mucosa
because nascent transcripts from the
circular DNA that is looped out during
the CSR process are detectable in
B cell preparations from the lamina
propria (Fagarasan et al., 2001). The
problem here is that there are hun-
dreds of tiny isolated lymphoid folli-
cles, probably functioning asminiature
Peyer’s patches, that potentially con-
taminate the experimentally isolated
lamina-propria leukocytes (Shikina
et al., 2004).
In this issue of Immunity, He et al.
have presented new evidence for local
lamina-propria CSR of IgA2 in the
human colon (He et al., 2007). Here, a
critical APRIL signal appears to come
mainly from colonocytes, although it
can also be detected in DCs and plas-
macytoid cells adjacent to the colonic
epithelium. The Caco-2 human intesti-
nal epithelial cell line is stimulated to
express APRIL by bacterial Toll-like re-
ceptor (TLR) ligands, lipopolysaccha-
ride (LPS), and flagellin, or by whole
bacteria. Alternatively, thymic stromal
lymphopoeitin (TSLP), which is pro-
duced by epithelial cells when they
are stimulated by whole bacteria, fla-
gellin, or peptidoglycan, will in turn
stimulate intestinal myeloid DC to
produce APRIL and IL-10 (Figure 1).
APRIL (and IL-10) is shown to stimu-
late local aCSR in colonic lamina-
propria B cells from detection of na-
scent transcripts of B cell preparationsex vivo, and by coculture experiments
in which either epithelial cells or mye-
loid DC expressing APRIL can stimu-
late naive IgD+ B cells to express IgA
in the presence of IL-10. Analysis of
the genomic splicing at the switch re-
gion after CSR suggests that most
B cells in the colon have switched
directly from IgM to IgA2, but there
are also some IgA1-IgA2 splice se-
quences, so IgA1 B cells from the
Peyer’s patches may later be stimu-
lated to switch to IgA2 when they
reach the colon after recirculation
(Figure 1). In immunodeficient patients
lacking CD4+ T cells or CD40 signal-
ing, IgA2 is produced normally, indi-
cating that this local CSR process is
T independent.
How does this leave the discrep-
ancy with mouse experiments that
cannot find evidence of CSR to IgA in
the lamina propria in CD40-deficient
animals despite clear positive controls
(Bergqvist et al., 2006)? Of course
there may be species differences, and
most experiments in mice have looked
at the small intestine rather than the
colon as studied by He et al. (2007) in
humans. Another factor is that the mi-
crobiota of most specific pathogen-
free laboratory mice is less dense and
composed of fewer species than that
in humans, so a transitory local CSR
process might simply be at a much
lower level and harder to detect. A
clear answer about this will await the
combination of epithelial-cell-specific
APRIL-deficient mouse experiments
combined with DC-depletion systems.
IgA is our most abundant immuno-
globulin, largely secreted across the
mucous membranes. About 3 g per
day of IgA is secreted into the human
intestine. It seems to be functionally
flexible with probable high-affinity
(neutralizing) and low-affinity (binding)Immunitsystems. The paper by He et al.
(2007) gives us new insight into the in-
teractions between colonic epithelial
cells and B cells in the lamina propria
as a T independent aCSR mechanism
that produces IgA2 capable of binding
bacterial surface molecules. The func-
tional consequences of IgA secretion
on the complex human microbial con-
sortia are still poorly understood, but
this should soonbe addressed through
metagenomics advances driven by the
new high-throughput highly parallel
sequencing systems.
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